A real-world, multicenter study of atezolizumab plus bevacizumab in viral and non-viral advanced hepatocellular carcinoma patients from Asia and Europe

被引：0

作者：

Rossari, F. ^{[1
]}

Tada, T. ^{[2
]}

Shimose, S. ^{[3
]}

Kudo, M. ^{[4
]}

Yoo, C. ^{[5
]}

Cheon, J. ^{[6
]}

Finkelmeier, F. ^{[7
]}

Lim, H. Y. ^{[8
]}

Presa, J. ^{[9
]}

Masi, G. ^{[10
]}

Bergamo, F. ^{[11
]}

Amadeo, E. ^{[12
]}

Vitiello, F. ^{[13
]}

Foti, S. ^{[14
]}

Camera, S. ^{[12
]}

Persano, M. ^{[15
]}

Stefanini, B. ^{[16
]}

Scartozzi, M. ^{[17
]}

Rimini, M. ^{[12
]}

Gardini, A. Casadei ^{[12
]}

机构：

[1] UniSR Univ Vita & Salute San Raffaele Milano, Dept Med Oncol, SR Tiget, Milan, Italy

[2] Japanese Red Cross Soc Himeji Hosp, Internal Med, Himeji, Japan

[3] Kurume Univ Hosp, Div Gastroenterol, Dept Med, Kurume, Japan

[4] Kindai Univ, Dept Gastroenterol & Hepatol, Fac Med, Osaka, Japan

[5] Univ Ulsan, Dept Med Oncol, Asan Med Ctr, Seoul, South Korea

[6] Ulsan Univ Hosp, Div Hematol & Oncol, Ulsan, South Korea

[7] Goethe Univ Frankfurt am Main, Gastroenterol Dept, Campus Westend, Frankfurt, Germany

[8] Sungkyunkwan Univ, Dept Med, Samsung Med Ctr SMC, Sch Med, Seoul, South Korea

[9] Ras os Montes & Alto Douro Hosp Ctr, Liver Unit, Vila Real, Portugal

[10] Pisa Univ, Dept Translat Res & New Technol Med & Surg, Pisa, Italy

[11] IOV Ist Oncol Veneto IRCCS, Oncol 1, Padua, Italy

[12] IRCCS Osped San Raffaele, Dept Med Oncol, Milan, Italy

[13] IRCCS Osped San Raffaele, Oncol, Milan, Italy

[14] IRCCS Osped San Raffaele, Dept Oncol, Milan, Italy

[15] AOU Cagliari Osped Civile, Dept Med Oncol, Cagliari, Italy

[16] Imperial Coll London, Oncol, Hammersmith Campus, London, England

[17] Univ Cagliari, Dept Med Oncol, Cagliari, Italy

来源：

ANNALS OF ONCOLOGY | 2024年 / 35卷

关键词：

D O I：

10.1016/j.annonc.2024.05.191

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

182P

引用

页码：S82 / S82

页数：1

共 50 条

[41] Real-world experience of atezolizumab and bevacizumab for treatment of advanced hepatocellular carcinoma in a single tertiary center
Raharjo, C. V.
Joseph, R.
Stratton, E.
Levy, M.
Prakoso, E.
JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY, 2023, 38 : 22 - 22
[42] Real-World Study of Systemic Treatment after First-Line Atezolizumab plus Bevacizumab for Hepatocellular Carcinoma in Asia-Pacific Countries
Lee, Choong-kun
Yoo, Changhoon
Hong, Jung Yong
Park, Se Jun
Kim, Jin Won
Tai, David Wai Meng
Kim, Hyeyeong
Korphaisarn, Krittiya
Tanasanvimon, Suebpong
Chen, San-Chi
Kim, Ju Won
Kim, Ilhwan
Kim, Moonho
Choo, Joan
Oh, Sang-Bo
Chen, Ching-Tso
Bae, Woo Kyun
Kim, Hongsik
Huh, Seok Jae
Yen, Chia-Jui
Park, Sejung
Lee, Dong Ki
Chan, Landon Long
Kang, Beodeul
Kang, Minsu
Sundar, Raghav
Choi, Hye Jin
Chan, Stephen Lam
Chon, Hong Jae
Lee, Myung-Ah
LIVER CANCER, 2024,
[43] Sorafenib vs. Lenvatinib in advanced hepatocellular carcinoma after atezolizumab/bevacizumab failure: A real-world study
Chon, Young Eun
Kim, Dong Yun
Kim, Mi Na
Kim, Beom Kyung
Kim, Seung Up
Park, Yong
Ahn, Sang Hoon
Ha, Yeonjung
Lee, Joo Ho
Lee, Kwan Sik
Kang, Beodeul
Kim, Jung Sun
Chon, Hong Jae
Kim, Do Young
CLINICAL AND MOLECULAR HEPATOLOGY, 2024, 30 (03)
[44] Atezolizumab plus bevacizumab (A plus B) in patients with unresectable hepatocellular carcinoma (uHCC): Real-world experience from a US community oncology network
Cosgrove, David
Tan, Amie
Osterland, Andrew
Hernandez, Sairy
Ogale, Sarika
Mahrus, Sami
Murphy, John
Wilson, Thomas W.
Patton, Gregory A.
Loaiza-Bonilla, Arturo
Singal, Amit G.
JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (3_SUPPL) : 447 - 447
[45] Significance of ramucirumab following atezolizumab plus bevacizumab therapy for hepatocellular carcinoma using real-world data
Shimose, Shigeo
Sugimoto, Rie
Hiraoka, Atsushi
Tanaka, Masatoshi
Iwamoto, Hideki
Tanaka, Yuki
Tada, Fujimasa
Ohama, Hideko
Niizeki, Takashi
Shirono, Tomotake
Moriyama, Etsuko
Noda, Yu
Kamachi, Naoki
Nakano, Masahito
Kuromatsu, Ryoko
Koga, Hironori
Kawaguchi, Takumi
HEPATOLOGY RESEARCH, 2023, 53 (02) : 116 - 126
[46] Combination of Radiotherapy and Atezolizumab plus Bevacizumab in Patients with Advanced Hepatocellular Carcinoma: A Pilot Study
Hur, Y. J.
Kim, J.
Seong, J.
Lee, C. K.
Kim, B. K.
Kim, D. Y.
INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2023, 117 (02): : E304 - E305
[47] Atezolizumab and bevacizumab for hepatocellular carcinoma: How to approach salvage therapy for non-responders?: Editorial on "Sorafenib vs. Lenvatinib in advanced hepatocellular carcinoma after atezolizumab/bevacizumab failure: A real-world study"
Nishida, Naoshi
CLINICAL AND MOLECULAR HEPATOLOGY, 2024, 30 (04)
[48] Real-world experience with atezolizumab plus bevacizumab (A plus /-B) in Hispanic patients with advanced hepatocellular carcinoma (HCC) at a Hispanic-majority cancer center.
Parekh, Jay
Newman, Neil
Arellano, Luisa Marie
Altermatt, Brittany
Salazar, Mary
Edwards, Shannon
Balasubramanian, Lakshmi
Denno, James
Fuentes, Lorena
Sun, LuZhe
Arora, Sukeshi Patel
JOURNAL OF CLINICAL ONCOLOGY, 2025, 43 (4_SUPPL) : 549 - 549
[49] Atezolizumab and Bevacizumab for Treatment of Patients With Unresectable / Non-transplantable Advanced Hepatocellular Carcinoma: A Real-World Single Center Experience from North India
Dhampalwar, Swapnil
Choudhary, Narendra S.
Saraf, Neeraj
Bhangui, Prashant
Soin, Arvinder S.
JOURNAL OF CLINICAL AND EXPERIMENTAL HEPATOLOGY, 2024, 14 (01)
[50] Real-world multi-center study of systemic treatment after first-line atezolizumab plus bevacizumab for advanced hepatocellular carcinoma in Asia-Pacific countries
Lee, C-K.
Yoo, C.
Park, S. J.
Kim, H.
Korphaisarn, K.
Kim, J. W.
Chen, S-C.
Kim, I.
Kim, M.
Chan, S. L.
Kim, J. W.
Tai, D. W. M.
Oh, S. B.
Chen, C-T.
Bae, W. K.
Kim, H.
Hong, J. Y.
Choi, H. J.
Chon, H. J.
Lee, M. A.
ANNALS OF ONCOLOGY, 2023, 34 : S603 - S603

← 1 2 3 4 5 →